General
Preferred name
ozanimod
Synonyms
RPC-1063 ()
Ozanimod (hydrochloride) ()
RPC1063 ()
OZANIMOD HYDROCHLORIDE ()
RPC-1063 (hydrochloride) ()
Ozanimod (RPC1063) ()
RPC-1063 HCL ()
Zeposia ()
RPC1063 HCL ()
P&D ID
PD049163
CAS
1306760-87-1
1618636-37-5
Tags
available
drug
Approved by
EMA
FDA
First approval
2020
Drug Status
investigational
approved
Drug indication
Multiple sclerosis
Crohn disease
Non-small-cell lung cancer
Ulcerative colitis
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Ozanimod (RPC1063) is a novel, orally available, specific and potent agonist of the sphingosine 1-phosphate 1 receptor (S1P1R) and SIP5Rs . Ozanimod is compound 86 in patent US20110172202 A1 , which specifies the (S)-enantiomer.
Ozanimod reduces chronic inflammation and alleviates kidney pathology in a mouse model of systemic lupus erythematosus (SLE), which suggests that ozanimod may offer clinical benefit as a SLE therapeutic . (GtoPdb)
Ozanimod reduces chronic inflammation and alleviates kidney pathology in a mouse model of systemic lupus erythematosus (SLE), which suggests that ozanimod may offer clinical benefit as a SLE therapeutic . (GtoPdb)
DESCRIPTION
Ozanimod (RPC1063) is a novel, orally available, specific and potent agonist of the sphingosine 1-phosphate 1 receptor (S1P1R) and SIP5Rs . Ozanimod is compound 86 in patent US20110172202 A1 , which specifies the (S)-enantiomer.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
20
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
NCATS Inxight Approved Drugs
Pandemic Response Box
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
36
Molecular Weight
404.18
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
3
cLogP
3.63
TPSA
104.2
Fraction CSP3
0.35
Chiral centers
1.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
S1P1
S1P5
S1PR1
LPL Receptor
S1P Receptor
MOA
sphingosine 1-phosphate receptor agonist
Source data
